Adult T-Cell leukemia/lymphoma in the Caribbean cohort is a distinct clinical entity with dismal response to conventional chemotherapy

Monica Zell, Amer Assal, Olga Derman, Noah Kornblum, Ramakrishna Battini, Yanhua Wang, Deepa M. Narasimhulu, Ioannis Mantzaris, Aditi Shastri, Amit K. Verma, B. Hilda Ye, Ira Braunschweig, Murali Janakiram

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Adult T-cell leukemia/lymphoma (ATLL) is a rare and aggressive disease caused by human T-cell lymphotropic virus type 1 that predominantly affects Japanese and Caribbean populations. Most studies have focused on Japanese cohorts. We conducted a retrospective analysis of 53 cases of ATLL who presented to our institution between 2003-2014. ATLL in the Caribbean population presents more often as the acute and lymphomatous subtypes, is associated with complex cytogenetics, and has a high rate of CNS involvement. The overall response rate to first-line therapies with anthracycline-based regimens was poor (32%), with a median survival of only 6.9 months. A complete or partial response to first-line regimens was associated with better survival. There was no difference in survival between patients who received chemotherapy alone versus chemotherapy with antiviral agents. Allogeneic transplantation was performed in five patients, two of whom achieved complete remission despite residual or refractory disease. Recipients of allogeneic transplantation had significantly improved overall survival compared to non-transplanted patients. This is the first analysis to describe ATLL pathological features, cytogenetics, and response to standard therapy and transplantation in the Caribbean cohort.

Original languageEnglish (US)
Pages (from-to)51981-51990
Number of pages10
JournalOncotarget
Volume7
Issue number32
DOIs
StatePublished - Aug 1 2016

Fingerprint

Adult T Cell Leukemia Lymphoma
Drug Therapy
Survival
Homologous Transplantation
Cytogenetics
Human T-lymphotropic virus 1
Anthracyclines
Rare Diseases
Population
Antiviral Agents
Transplantation
T-Lymphocytes
Therapeutics

Keywords

  • Adult T-cell leukemia/lymphoma (ATLL)
  • Allogeneic stem cell transplantation
  • Human T-cell lymphotropic virus type-1 (HTLV-1)
  • Non-Hodgkin lymphoma
  • T-cell lymphoma

ASJC Scopus subject areas

  • Oncology

Cite this

Adult T-Cell leukemia/lymphoma in the Caribbean cohort is a distinct clinical entity with dismal response to conventional chemotherapy. / Zell, Monica; Assal, Amer; Derman, Olga; Kornblum, Noah; Battini, Ramakrishna; Wang, Yanhua; Narasimhulu, Deepa M.; Mantzaris, Ioannis; Shastri, Aditi; Verma, Amit K.; Ye, B. Hilda; Braunschweig, Ira; Janakiram, Murali.

In: Oncotarget, Vol. 7, No. 32, 01.08.2016, p. 51981-51990.

Research output: Contribution to journalArticle

@article{9338b9c3a45f459cacd48a610e6a66f0,
title = "Adult T-Cell leukemia/lymphoma in the Caribbean cohort is a distinct clinical entity with dismal response to conventional chemotherapy",
abstract = "Adult T-cell leukemia/lymphoma (ATLL) is a rare and aggressive disease caused by human T-cell lymphotropic virus type 1 that predominantly affects Japanese and Caribbean populations. Most studies have focused on Japanese cohorts. We conducted a retrospective analysis of 53 cases of ATLL who presented to our institution between 2003-2014. ATLL in the Caribbean population presents more often as the acute and lymphomatous subtypes, is associated with complex cytogenetics, and has a high rate of CNS involvement. The overall response rate to first-line therapies with anthracycline-based regimens was poor (32{\%}), with a median survival of only 6.9 months. A complete or partial response to first-line regimens was associated with better survival. There was no difference in survival between patients who received chemotherapy alone versus chemotherapy with antiviral agents. Allogeneic transplantation was performed in five patients, two of whom achieved complete remission despite residual or refractory disease. Recipients of allogeneic transplantation had significantly improved overall survival compared to non-transplanted patients. This is the first analysis to describe ATLL pathological features, cytogenetics, and response to standard therapy and transplantation in the Caribbean cohort.",
keywords = "Adult T-cell leukemia/lymphoma (ATLL), Allogeneic stem cell transplantation, Human T-cell lymphotropic virus type-1 (HTLV-1), Non-Hodgkin lymphoma, T-cell lymphoma",
author = "Monica Zell and Amer Assal and Olga Derman and Noah Kornblum and Ramakrishna Battini and Yanhua Wang and Narasimhulu, {Deepa M.} and Ioannis Mantzaris and Aditi Shastri and Verma, {Amit K.} and Ye, {B. Hilda} and Ira Braunschweig and Murali Janakiram",
year = "2016",
month = "8",
day = "1",
doi = "10.18632/oncotarget.10223",
language = "English (US)",
volume = "7",
pages = "51981--51990",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "32",

}

TY - JOUR

T1 - Adult T-Cell leukemia/lymphoma in the Caribbean cohort is a distinct clinical entity with dismal response to conventional chemotherapy

AU - Zell, Monica

AU - Assal, Amer

AU - Derman, Olga

AU - Kornblum, Noah

AU - Battini, Ramakrishna

AU - Wang, Yanhua

AU - Narasimhulu, Deepa M.

AU - Mantzaris, Ioannis

AU - Shastri, Aditi

AU - Verma, Amit K.

AU - Ye, B. Hilda

AU - Braunschweig, Ira

AU - Janakiram, Murali

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Adult T-cell leukemia/lymphoma (ATLL) is a rare and aggressive disease caused by human T-cell lymphotropic virus type 1 that predominantly affects Japanese and Caribbean populations. Most studies have focused on Japanese cohorts. We conducted a retrospective analysis of 53 cases of ATLL who presented to our institution between 2003-2014. ATLL in the Caribbean population presents more often as the acute and lymphomatous subtypes, is associated with complex cytogenetics, and has a high rate of CNS involvement. The overall response rate to first-line therapies with anthracycline-based regimens was poor (32%), with a median survival of only 6.9 months. A complete or partial response to first-line regimens was associated with better survival. There was no difference in survival between patients who received chemotherapy alone versus chemotherapy with antiviral agents. Allogeneic transplantation was performed in five patients, two of whom achieved complete remission despite residual or refractory disease. Recipients of allogeneic transplantation had significantly improved overall survival compared to non-transplanted patients. This is the first analysis to describe ATLL pathological features, cytogenetics, and response to standard therapy and transplantation in the Caribbean cohort.

AB - Adult T-cell leukemia/lymphoma (ATLL) is a rare and aggressive disease caused by human T-cell lymphotropic virus type 1 that predominantly affects Japanese and Caribbean populations. Most studies have focused on Japanese cohorts. We conducted a retrospective analysis of 53 cases of ATLL who presented to our institution between 2003-2014. ATLL in the Caribbean population presents more often as the acute and lymphomatous subtypes, is associated with complex cytogenetics, and has a high rate of CNS involvement. The overall response rate to first-line therapies with anthracycline-based regimens was poor (32%), with a median survival of only 6.9 months. A complete or partial response to first-line regimens was associated with better survival. There was no difference in survival between patients who received chemotherapy alone versus chemotherapy with antiviral agents. Allogeneic transplantation was performed in five patients, two of whom achieved complete remission despite residual or refractory disease. Recipients of allogeneic transplantation had significantly improved overall survival compared to non-transplanted patients. This is the first analysis to describe ATLL pathological features, cytogenetics, and response to standard therapy and transplantation in the Caribbean cohort.

KW - Adult T-cell leukemia/lymphoma (ATLL)

KW - Allogeneic stem cell transplantation

KW - Human T-cell lymphotropic virus type-1 (HTLV-1)

KW - Non-Hodgkin lymphoma

KW - T-cell lymphoma

UR - http://www.scopus.com/inward/record.url?scp=84982242193&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982242193&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.10223

DO - 10.18632/oncotarget.10223

M3 - Article

C2 - 27341021

AN - SCOPUS:84982242193

VL - 7

SP - 51981

EP - 51990

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 32

ER -